Related references
Note: Only part of the references are listed.Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation
Sabrina Baltschukat et al.
CLINICAL CANCER RESEARCH (2019)
Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer
Gillianne Gy Lai et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Feasibility of lung cancer prediction from low-dose CT scan and smoking factors using causal models
Vineet K. Raghu et al.
THORAX (2019)
DNA-Based versus RNA-Based Detection of MET Exon 14 Skipping Events in Lung Cancer
Kurtis D. Davies et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Patient and carer perceived barriers to early presentation and diagnosis of lung cancer: a systematic review
Shemana Cassim et al.
BMC CANCER (2019)
Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib
Seulki Kim et al.
CANCER RESEARCH AND TREATMENT (2019)
Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors
D. Westover et al.
ANNALS OF ONCOLOGY (2018)
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology
Neat I. Lindeman et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2018)
Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers
Alexander Drilon et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Clinical analysis by next-generation sequencing for NSCLC patients with &ITMET&IT amplification resistant to osimertinib
Yubo Wang et al.
LUNG CANCER (2018)
Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer - A systematic review and meta-analysis
Huy Gia Vuong et al.
LUNG CANCER (2018)
Third generation EGFR TKIs: current data and future directions
Chee-Seng Tan et al.
MOLECULAR CANCER (2018)
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
J. -C. Soria et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib
Kiichiro Ninomiya et al.
SCIENTIFIC REPORTS (2018)
Symptom Signatures and Diagnostic Timeliness in Cancer Patients: A Review of Current Evidence
Minjoung M. Koo et al.
NEOPLASIA (2018)
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
D. Planchard et al.
ANNALS OF ONCOLOGY (2018)
PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers
J. K. Sabari et al.
ANNALS OF ONCOLOGY (2018)
Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer
Yi-Long Wu et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Crizotinib in patients (pts) with MET-amplified non-small cell lung cancer (NSCLC): Updated safety and efficacy findings from a phase 1 trial.
D. Ross Camidge et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
LBA50Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study
S S Ramalingam et al.
ANNALS OF ONCOLOGY (2018)
A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification
Eric Angevin et al.
EUROPEAN JOURNAL OF CANCER (2017)
Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung
David R. Spigel et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer
Toni K. Choueiri et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Non-Small Cell Lung Cancer, Version 5.2017 Clinical Practice Guidelines in Oncology
David S. Ettinger et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2017)
TATTON Ph Ib Expansion Cohort: Osimertinib plus Savolitinib for Pts with EGFR-Mutant MET-Amplified NSCLC after Progression on Prior EGFR-TKI
M. Ahn et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Antitumor Activity and Safety of Crizotinib in Patients with MET Exon 14-Altered Advanced Non-Small Cell Lung Cancer
Alex Drilon et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Responses to Crizotinib Can Occur in High-Level MET-Amplified Non-Small Cell Lung Cancer Independent of MET Exon 14 Alterations
Rafael Caparica et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable
Thanyanan Reungwetwattana et al.
LUNG CANCER (2017)
MET overexpression and gene amplification: prevalence, clinico-pathological characteristics and prognostic significance in a large cohort of patients with surgically resected NSCLC
William Sterlacci et al.
VIRCHOWS ARCHIV (2017)
Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations
Keita Masuzawa et al.
ONCOTARGET (2017)
MET inhibitors in advanced non-small-cell lung cancer: a meta-analysis and review
Jung Han Kim et al.
ONCOTARGET (2017)
Hepatocyte Growth Factor, a Key Tumor-Promoting Factor in the Tumor Microenvironment
Benjamin Yaw Owusu et al.
CANCERS (2017)
Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non-Small-Cell Lung Cancer
Matthew S. Lara et al.
CLINICAL LUNG CANCER (2017)
MET amplification (amp) as a resistance mechanism to osimertinib.
Zofia Piotrowska et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Efficacy and Safety Results From a Phase II, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy for Advanced Squamous Cell Non-Small-Cell Lung Cancer
Fred R. Hirsch et al.
CLINICAL LUNG CANCER (2017)
A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer
Alexander Drilon et al.
CLINICAL CANCER RESEARCH (2016)
MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-Life
Alexander Drilon
CLINICAL CANCER RESEARCH (2016)
MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis
Joanna H. Tong et al.
CLINICAL CANCER RESEARCH (2016)
MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression
Mark M. Awad et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations
Xuewen Liu et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis
Sinead A. Noonan et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations
Alexa B. Schrock et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models
Paul E. Hughes et al.
MOLECULAR CANCER THERAPEUTICS (2016)
MET Exon 14 Skipping in Non-Small Cell Lung Cancer
Rebecca S. Heist et al.
ONCOLOGIST (2016)
Symptoms and other factors associated with time to diagnosis and stage of lung cancer: a prospective cohort study
F. M. Walter et al.
BRITISH JOURNAL OF CANCER (2015)
Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer
Giorgio Scagliotti et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping
Paul K. Paik et al.
CANCER DISCOVERY (2015)
Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors
Garrett M. Frampton et al.
CANCER DISCOVERY (2015)
Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study
David Cunningham et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Comprehensive molecular profiling of lung adenocarcinoma
Eric A. Collisson et al.
NATURE (2014)
Prognostic Value of MET Gene Copy Number and Protein Expression in Patients with Surgically Resected Non-Small Cell Lung Cancer: A Meta-Analysis of Published Literatures
Baoping Guo et al.
PLOS ONE (2014)
MET Gene Copy Number Predicts Worse Overall Survival in Patients with Non-Small Cell Lung Cancer (NSCLC); A Systematic Review and Meta-Analysis
Anastasios Dimou et al.
PLOS ONE (2014)
Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors
Elizabeth C. Smyth et al.
ONCOTARGETS AND THERAPY (2014)
Targeting MET Amplification as a New Oncogenic Driver
Hisato Kawakami et al.
CANCERS (2014)
Tivantinib plus erlotinib versus placebo plus erlotinib in Asian patients with previously treated nonsquamous NSCLC with wild-type EGFR: First report of a phase III ATTENTION trial.
Koichi Azuma et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Cytotoxic Activity of Tivantinib (ARQ 197) Is Not Due Solely to c-MET Inhibition
Ryohei Katayama et al.
CANCER RESEARCH (2013)
Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004-2007
Sarah Walters et al.
THORAX (2013)
Crizotinib for the Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: A Success Story to Usher in the Second Decade of Molecular Targeted Therapy in Oncology
Sai-Hong Ignatius Ou et al.
ONCOLOGIST (2012)
A Novel Kinase Inhibitor, INCB28060, Blocks c-MET-Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3
Xiangdong Liu et al.
CLINICAL CANCER RESEARCH (2011)
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Lecia V. Sequist et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer
Eunice L. Kwak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Increased MET Gene Copy Number Negatively Affects Survival of Surgically Resected Non-Small-Cell Lung Cancer Patients
Federico Cappuzzo et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Activation of MET by Gene Amplification or by Splice Mutations Deleting the Juxtamembrane Domain in Primary Resected Lung Cancers
Ryoichi Onozato et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer
Katsuhiro Okuda et al.
CANCER SCIENCE (2008)
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
James Bean et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
Manabu Soda et al.
NATURE (2007)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
An orally available small-molecule inhibitor of c-met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms
Helen Y. Zou et al.
CANCER RESEARCH (2007)
Share Paper
